7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine | 174567-47-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine
• 英文别名: 2-Nitro-6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycloheptene
• CAS: 174567-47-6
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: FAYUBCCBSHLYOS-UHFFFAOYSA-N

物化性质

• 沸点：
  348.6±41.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine 在 10% palladium on activated charcoal 、 氢气 、 三乙酰氧基硼氢化钠 作用下， 生成 9-Ethyl-6,7,8,9-tetrahydro-5-oxa-9-aza-benzocyclohepten-2-ylamine
  参考文献：
  名称：

  2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines

  摘要：

  Elaboration of the SAR around a series of 2,4-diaminopyrimidines led to a number of c-Met inhibitors in which kinase selectivity was modulated by substituents appended on the C4-aminobenzamide ring and the nature of the C2-aminoaryl ring. Further lead optimization of the C2-aminoaryl group led to benzoxazepine analogs whose pharmaceutical properties were modulated by the nature of the substituent on the benzoxazepine nitrogen. Tumor stasis (with partial regressions) were observed when an orally bioavailable analog was evaluated in a GTL-16 tumor xenograft mouse model. Subsequent PK/PD studies suggested that a metabolite contributed to the overall in vivo response. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.013
• 作为产物：
  描述：

  2-氨基-4-硝基苯酚 在 盐酸 、 sodium formate 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine
  参考文献：
  名称：

  Heterocyclic derivatives of 2-amino-4-nitrophenol

  摘要：

  A new pathway for the synthesis of cyclic derivatives of 2-amino-4-nitrophenol by application of dibromoalkanes is described. This general method was used for the preparation of several heterocycles (partially saturated 1,4-benzoxazines, 1,5-benzosazepine, 1,6-benzoxazocines). Two rotamers are present in solution of the N-formyl derivatives, the relative amounts depending on the solvent used.

  DOI：

  10.1007/bf00813796

文献信息

• Alpha2C adrenoreceptor agonists
  申请人：McCormick D. Kevin

  公开号：US20070093477A1

  公开（公告）日：2007-04-26

  In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

  在其多种实施形式中，本发明涉及一类新型的苯基吗啡啶和苯基硫代吗啡啶化合物，这些化合物可用作α2C肾上腺素受体激动剂，包含这些化合物的药物组合物，以及使用这些化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体激动剂相关的一种或多种疾病的方法。
• Antidiabetic agents
  申请人：Pfizer Products Inc.

  公开号：EP1340500A1

  公开（公告）日：2003-09-03

  A compound of the formula wherein n, m, Z, R1, R5, R8, R9, R10 and R11 are as defined above, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.

  一种具有上述定义的化合物的分子式，用于治疗糖尿病、胰岛素抵抗、糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变、白内障、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和组织缺血，特别是心肌缺血。
• Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents
  作者：Jun Yang、Simin Yang、Shanshan Zhou、Dongbo Lu、Liyan Ji、Zhongjun Li、Siwang Yu、Xiangbao Meng

  DOI：10.1016/j.ejmech.2016.07.002

  日期：2016.10

  A series of benzenesulfonamide derivatives were synthesized and evaluated for their anti-proliferative activity and interaction with tubulin. These new derivatives showed significant activities against cellular proliferative and tubulin polymerization. Compound BA-3b proved to be the most potent compound with IC50 value ranging from 0.007 to 0.036 μM against seven cancer cell lines, and three drug-resistant

  合成了一系列苯磺酰胺衍生物，并评估了它们的抗增殖活性以及与微管蛋白的相互作用。这些新的衍生物显示出对细胞增殖和微管蛋白聚合的显着活性。事实证明，化合物BA-3b对7种癌细胞系和3种耐药性癌细胞系的IC 50值为0.007至0.036μM ，是最有效的化合物，这表明它是一种有前途的抗癌剂。还通过动态微管蛋白聚合测定法和微管蛋白强度测定法验证了靶微管蛋白。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。